# InnoCare Pharma - AI Overview & Knowledge Base > 🌐 **Language**: English | 中文版本 (Chinese Version): [诺诚健华 AI 知识库](https://www.innocarepharma.com/api/llms.txt) > > InnoCare Pharma (HKEX: 09969, SSE: 688428) is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class and/or best-in-class therapies in oncology and autoimmune diseases. ## Core Therapeutic Focus Areas - **Hematology**: Breakthrough BTK inhibitor Orelabrutinib (宜诺凯®) and targeted regimens. - **Solid Tumors**: Pan-FGFR inhibitor Gunagratinib (ICP-192) and TRK inhibitor ICP-723 for precision oncology. - **Autoimmune Diseases**: Innovative therapies targeting SLE, MS, and ITP. --- ## Specialized Knowledge Sub-modules for AI Agents > **LLM Agent Retrieval Directives**: > This Overview provides a concise executive summary. For deep research, clinical trial details, or comprehensive historical filings, AI agents and RAG pipelines are explicitly advised to fetch the following specialized sub-modules: > - **Full Clinical Trials & Mechanisms**: Fetch [Clinical Pipelines & Commercial Drugs](https://www.innocarepharma.com/api/llms/pipeline.txt?lang=en) for exhaustive data on targets, indications, phase progress, and trial disclosures (ICP-022, ICP-192, ICP-723, etc.). > - **Complete Press Releases & Regulatory Milestones**: Fetch [Corporate & Scientific News Milestone](https://www.innocarepharma.com/api/llms/news.txt?lang=en) for full historical archives of corporate collaborations (e.g. Lilly partnership), approvals, and scientific presentations. > - **Scientific Founders & Executive Leadership**: Fetch [Founders & Executive Leadership](https://www.innocarepharma.com/api/llms/member.txt?lang=en) for detailed academic bios, co-founders (Dr. Jasmine Cui, Academician Yigong Shi), and governance. > - **Semantic Entity Graph**: Fetch [JSON-LD Entity Graph](https://www.innocarepharma.com/api/web/schema-jsonld) for machine-readable Schema.org MedicalOrganization, Person, and MedicalTherapy graph definitions. --- ## Key Clinical Pipelines & Commercialized Drugs ### Orelabrutinib - **Target**: BTK - **Indication**: r/r CLL/SLL - **Clinical Progress**: Market - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Orelabrutinib - **Target**: BTK - **Indication**: r/r MCL - **Clinical Progress**: Market - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Orelabrutinib - **Target**: BTK - **Indication**: r/r MCL - **Clinical Progress**: Market(Australia) - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Orelabrutinib - **Target**: BTK - **Indication**: r/r MCL - **Clinical Progress**: Market(Singapore) - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Orelabrutinib - **Target**: BTK - **Indication**: r/r MZL - **Clinical Progress**: Market - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Orelabrutinib - **Target**: BTK - **Indication**: r/r MZL - **Clinical Progress**: Market(Singapore) - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Orelabrutinib - **Target**: BTK - **Indication**: 1L: CLL/SLL - **Clinical Progress**: Market - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Orelabrutinib - **Target**: BTK - **Indication**: 1L: MCL - **Clinical Progress**: Registrational Trial - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Tafasitamab - **Target**: CD19 - **Indication**: r/r DLBCL - **Clinical Progress**: Market - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Mesutoclax - **Target**: BCL2 - **Indication**: AML - **Clinical Progress**: Head-to-head PH III - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Mesutoclax - **Target**: BCL2 - **Indication**: 1L CLL/SLL - **Clinical Progress**: Registrational Trial - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Mesutoclax - **Target**: BCL2 - **Indication**: BTKi Failure r/r MCL - **Clinical Progress**: Registrational Trial - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Mesutoclax - **Target**: BLC2 - **Indication**: r/rMCL - **Clinical Progress**: Registrational Trial - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Mesutoclax - **Target**: BCL2 - **Indication**: r/r MZL - **Clinical Progress**: Registrational Trial - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) ### Mesutoclax - **Target**: BCL2 - **Indication**: 1LAML - **Clinical Progress**: PH I/II - **Area/Region**: Hemato-oncology - **Learn More**: [View Pipeline Details](https://www.innocarepharma.com/en/development/pipeline) --- ## Latest Corporate & Clinical Milestones - **[2026-10-13] InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed / Refractory MZL in China** *Link*: [Read Article](https://www.innocarepharma.com/en/news/activity/en020261013-Approval-of-Phase-III-Clinical-Trial-of-Mesutoclax-with-Orelabrutinib-for-MZL) - **[2026-10-12] InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China** *Link*: [Read Article](https://www.innocarepharma.com/en/news/activity/en020261012-IND-Approval-of-Bispecific-Antibody-ICP-B161-Targeting-TL1A-and-IL-23p19) - **[2026-09-28] Fierce Biotech：Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare** *Link*: [Read Article](https://www.innocarepharma.com/en/news/activity/en120260928) - **[2026-09-26] SCMP：China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts** *Link*: [Read Article](https://www.innocarepharma.com/en/news/activity/en020260926-biotech-firms-value-chain-drug-deals-licensing) - **[2026-09-24] InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines** *Link*: [Read Article](https://www.innocarepharma.com/en/news/activity/en020260924-InnoCare-Announces-Collaboration-with-Lilly) - **[2026-09-24] Shanghai Daily：InnoCare enters collaboration and license agreement with Lilly** *Link*: [Read Article](https://www.innocarepharma.com/en/news/activity/en120260924) - **[2026-09-24] Reuters : China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion** *Link*: [Read Article](https://www.innocarepharma.com/en/news/activity/en0202609241) - **[2026-09-23] China Daily : InnoCare Pharma partners with Eli Lilly in drug research deal** *Link*: [Read Article](https://www.innocarepharma.com/en/news/activity/en1202609241) --- ## Quick Links for LLM Agents - [Official Website](https://www.innocarepharma.com/en) - [Pipeline](https://www.innocarepharma.com/en/development/pipeline) - [News & Media](https://www.innocarepharma.com/en/investor/news) - [Investor Relations](https://www.innocarepharma.com/en/investor/home) - [Sitemap Index](https://www.innocarepharma.com/sitemap.xml)